Korsana (KRSA) news
Recent news
Korsana Biosciences, Inc.: Wedbush initiates coverage with outperform rating; target price $44
Wedbush Securities has initiated coverage on Korsana Biosciences, Inc. (KRSA) with an "outperform" rating and a target price of $44 per share. This move comes as the biotechnology firm prepares to release its next quarterly earnings report on November 10, 2026. Korsana has reported consistent net…
AInvest Wire · 5h agoKorsana Biosciences, Inc.: Stifel initiates coverage with buy rating; target price $43
Stifel has initiated coverage of Korsana Biosciences, Inc. (NASDAQ: KORS) with a "buy" rating and a target price of $43 per share. The firm cited the company’s progress in its clinical pipeline and strategic positioning in the biotechnology sector as key factors in its recommendation. Korsana…
AInvest Wire · Sep 14, 2026Korsana Biosciences, Inc.: TD Cowen initiates coverage with buy rating
AInvest Wire · Sep 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.